Proactive Investors - Run By Investors For Investors

Admedus divesting non-core business; to focus on ADAPT product portfolio

The restructure will enable the company to improve working capital management and reduce cash burn through reduction in headcount.
Australian dollars
Admedus generated $11 million in revenue from its ADAPT products in 2018

Admedus Ltd (ASX:AHZ) has entered into an agreement to sell part of its Infusion business to a subsidiary of BTC Health Ltd (ASX:BTC) for $6.3 million.

This will complete the first phase of the Infusion business divestiture. Completion of the sale is subject to certain conditions being satisfied with the sale expected to complete in late May 2019.


Admedus generated $11 million in revenue from its ADAPT® products in 2018, and has steadily been reducing the selling, general and administration costs relative to revenue, as global sales of the ADAPT® product portfolio increases.

The spin-off of Infusion will allow the company to pursue its global growth strategy to focus the business on the commercial growth and development of ADAPT®.

Once the transaction is complete, Admedus’ headcount is expected to reduce by about 19%.

Phase I of the Infusion divestiture is part of the overall company restructuring plans that are underway.

READ: Admedus to spin-off immunotherapies business; shares surge

Admedus managing director and CEO Wayne Paterson said: “The restructure will enable us to improve working capital management and reduce cash burn through reduction in headcount and focus on the ADAPT® portfolio - which is delivering revenue growth and offers significant potential for future value creation as we grow global sales and advance the TAVR device into human clinical trials.”

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
lab worker
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use